¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"gene expression regulation, neoplastic"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • metabolic regulation
    ´ë»çÁ¶Àý
  • osmotic regulation
    »ïÅõ¾ÐÁ¶Àý
  • regulation
    1. ±ÔÁ¤ 2. Á¶Àý
  • up-regulation
    »óÇâÁ¶Àý
  • autosomal gene
    º¸Åë¿°»öüÀ¯ÀüÀÚ
  • additive gene
    »ó°¡À¯ÀüÀÚ
  • allelic gene
    ´ë¸³À¯ÀüÀÚ
  • complementary gene
    º¸Á·À¯ÀüÀÚ, »óÈ£º¸ÃæÀ¯ÀüÀÚ
  • control gene
    Á¦¾îÀ¯ÀüÀÚ
  • cooperating gene
    Çùµ¿À¯ÀüÀÚ
  • catabolite (gene) activator protein
    ºÐÇØ´ë»ç»ê¹°(À¯ÀüÀÚ)Ȱ¼º´Ü¹éÁú
  • calcitonin gene-related peptide
    Ä®½ÃÅä´ÑÀ¯ÀüÀÚ°ü·ÃÆéƼµå
  • candidate gene
    Èĺ¸À¯ÀüÀÚ
  • duplicate gene
    º¹»çÀ¯ÀüÀÚ
  • determinant gene
    °áÁ¤À¯ÀüÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • ionic regulation
    ÀÌ¿ÂÁ¶Àý
  • metabolic regulation
    ´ë»çÁ¶Àý
  • osmotic regulation
    »ïÅõ¾ÐÁ¶Àý
  • regulation
    ±ÔÁ¤, Á¶Àý
  • respiration regulation
    È£ÈíÁ¶Àý
  • self regulation
    ÀÚ°¡Á¶Àý
  • temperature regulation
    ü¿ÂÁ¶Àý
  • toxic chemical regulation
    µ¶¼ºÈ­Çй°Áú±ÔÁ¤
  • additive gene
    »ó°¡À¯ÀüÀÚ
  • allelic gene
    ´ë¸³À¯ÀüÀÚ
  • autosomal gene
    º¸Åë¿°»öüÀ¯ÀüÀÚ
  • gene amplification
    À¯ÀüÀÚÁõÆø
  • gene analysis
    À¯ÀüÀںм®
  • complementary gene
    º¸Á·À¯ÀüÀÚ, »óÈ£º¸ÃæÀ¯ÀüÀÚ
  • control gene
    Á¦¾îÀ¯ÀüÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • DP gene
    DPÀ¯ÀüÀÚ
  • DQ gene
    DQÀ¯ÀüÀÚ
  • DR gene
    DRÀ¯ÀüÀÚ
  • Gag gene
    gag À¯Àü(ÀÎ)ÀÚ
  • Gene therapy
    À¯ÀüÀÚÄ¡·á(ö½Öû)
  • Hfr mediated gene transfer
    °íºóµµÀçÁ¶ÇÕ¼¼Æ÷¸Å°³ À¯ÀüÀÚÀüÀÌ
  • Onc gene
    Onc À¯ÀüÀÚ
  • Src gene
    Src À¯Àü(ÀÎ)ÀÚ
  • T cell receptor gene
    T¼¼Æ÷[Ç׿ø]¼ö¿ëü À¯ÀüÀÚ
  • additive gene
    »ó°¡À¯ÀüÀÚ(ßÓÊ¥ë¶îîí­).
  • aniridia,pax-6 gene
    PAX-6 À¯ÀüÀÚ(¡­ë¶îîí­)
  • apc gene
    APC À¯ÀüÀÚ(¡­ë¶îîí­)
  • gene
    À¯ÀüÀÚ(ë¶îîí­)
  • gene
    À¯ÀüÀÚ
  • gene amplification
    À¯ÀüÀÚÁõÆø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • manual expression
    ¿ë¼öÇ¥Çö(¼ú)(¡­Ç¥Çö¼ú).
  • muscles of expression
    Ç¥Á¤±Ù(øúï×ÐÉ).
  • muscles of expression
    Ç¥Á¤±Ù
  • perfect square expression
    ¿ÏÀüÆò¹æ½Ä(èÇîïøÁÛ°ãÒ).
  • phenotypic expression
    Ç¥ÇöÇüÃâÇö.
  • down regulation
    ÇÏÇâÁ¶Àý
  • down-regulation (of receptors)
    (¼ö¿ëü)ÇÏÇâÁ¶Àý.
  • down-regulation (of receptors)
    ¼ö¿ëü(áôé»ô÷)ÇÏÇâÁ¶Àý(ù»ú¾ðàï½).
  • genetic regulation
    À¯ÀüÀûÁ¶Àý
  • genetic regulation
    À¯ÀüÀû Á¶Àý.
  • global regulation
    Åë°ýÁ¶Àý
  • heat regulation
    ü¿Â(¿­)Á¶Àý(ô÷è®æððàï½).
  • humoral regulation
    ü¾×¼º Á¶Àý(ðàï½).
  • ionic regulation
    ÀÌ¿ÂÁ¶Àý.
  • osmoregulation =osmotic regulation
    »ïÅõ¾ÐÁ¶Àý(¡­ðàï½).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cytoplasmic gene
    ¼¼Æ÷Áú À¯ÀüÀÚ(á¬øàòõë¶îîí­)
  • D gene
    D À¯ÀüÀÚ(ë¶îîí­)
  • dispensable gene
    ºñÇʼö À¯ÀüÀÚ(Þªù±âÎë¶îîí­) (ÔÒ) nonessential gene
  • diversity gene
    ´Ù¾ç¼º À¯ÀüÀÚ(ÒýåÆàõë¶îîí­) = D gene
  • dominant gene
    ¿ì¼º À¯ÀüÀÚ(éÐàõë¶îîí­)
  • duplicate gene
    º¹»ç À¯ÀüÀÚ(ÜÜÞÐë¶îîí­)
  • early gene
    Á¶±â À¯ÀüÀÚ (ðÄÑ¢ë¶îîí­)
  • epistatic gene
    ¿ìÀ§ À¯ÀüÀÚ (éÐêÈë¶îîí­)
  • essential gene
    Çʼö À¯ÀüÀÚ (ù±âÎë¶îîí­)
  • fused gene
    À¶ÇÕ À¯ÀüÀÚ(ë×ùêë¶îîí­)
  • fusion gene
    À¶ÇÕ À¯ÀüÀÚ(ë×ùêë¶îîí­)
  • gene
    À¯ÀüÀÚ(ë¶îîí­)
  • gene activation
    À¯ÀüÀÚ È°¼ºÈ­(ë¶îîí­üÀàõûù)
  • gene amplification
    À¯ÀüÀÚ ÁõÆø(ë¶îîí­ñòøë)
  • gene bank
    À¯ÀüÀÚ ÀºÇà(ë¶îîí­ëÞú¼)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MAIN medication-induced, autoimmune, infectious, and neoplastic [diseases associated with antiphospholipi...
NBP needle biopsy of prostate; neoplastic brachial plexopathy; nucleic acid binding protein
ND Doctor of Naturopathy; nasal deformity; natural death; Naval Dispensary; neonatal death; neoplastic ...
Neo neomycin; neoplasm or neoplastic
NG nasogastric; neoplastic growth; new growth; nitroglycerin; nodose ganglion; no growth; not given
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
IVET In vivo expression technology
STAXI State Trait Anger Expression Inventory
ELC expression linked copy
ES expression site
16S rDNA 16S rRNA gene
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • ionic regulation
    À̿ Á¶Àý
  • osmotic regulation
    »ïÅõ¾Ð Á¶Àý
  • paracrine regulation
    ÁÖÀ§ ºÐºñ Á¶Àý
  • regulation of body temperature
    ü¿Â Á¶Àý
  • safety regulation and standard
    ¾ÈÀü Á¶Àý ¹× Ç¥ÁØ
  • self-regulation
    ÀÚ°¡ Á¶Àý
  • thermal regulation
    ¿Âµµ Á¶Àý
    ¿ÂµµÀÇ º¯È­¿¡ ÀûÀÀÇÏ¿© ¿Âµµ¸¦ ¾Ë¸Â°Ô ¸ÂÃß´Â ÇàÀ§.
  • allelic gene
    ´ë¸³ À¯ÀüÀÚ
  • C-jun gene
    ¾¾-ÁØ À¯ÀüÀÚ
  • cancer suppressor gene
    ¾Ï ¾ïÁ¦ À¯ÀüÀÚ
  • contiguous gene syndrome
    Á¢Ã˼º À¯ÀüÀÚ ÁõÈıº
  • control gene
    Á¦¾î À¯ÀüÀÚ
  • dominant gene
    ¿ì¼º À¯ÀüÀÚ
  • duplicate gene
    Áߺ¹ À¯Àü ÀÎÀÚ
  • exaggeration gene
    °­Á¶ À¯ÀüÀÚ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
neoplastic <oncology, pathology> Pertaining to or like a neoplasm with new and abnormal growth, pertaining to neoplasia with the formation of a neoplasm.
Origin: Gr. Plassein = to form
(18 Nov 1997)
neoplastic arachnoiditis Infiltration of subarachnoid space by neoplastic cells, typically medulloblastoma or metastatic carcinoma.
Synonym: neoplastic arachnoiditis.
(05 Mar 2000)
neoplastic endocrine-like syndromes Endocrine syndromes due to hormone production by neoplasms of non-endocrine tissue, or by other than the usual endocrine tissues. They are often the first indication of a previously undetected neoplasm.
(12 Dec 1998)
neoplastic meningitis Infiltration of subarachnoid space by neoplastic cells, typically medulloblastoma or metastatic carcinoma.
Synonym: neoplastic arachnoiditis.
(05 Mar 2000)
neoplastic processes The pathological mechanisms and forms taken by tissue during degeneration into a neoplasm and its subsequent activity.
(12 Dec 1998)
neoplastic syndromes, hereditary The condition of a pattern of malignancies within a family, but not every individual's necessarily having the same neoplasm. Characteristically the tumour tends to occur at an earlier than average age, individuals may have more than one primary tumour, the tumours may be multicentric, usually more than 25 percent of the individuals in direct lineal descent from the proband are affected, and the cancer predisposition in these families behaves as an autosomal dominant trait with about 60 percent penetrance.
(12 Dec 1998)
appetite regulation Physiologic mechanisms which regulate or control the appetite and food intake.
(12 Dec 1998)
regulation 1. <biology> The adaption of form or behaviour of an organism to changed conditions.
2. <embryology> The power of a pregastrula stage to form a whole embryo from a part.
Origin: L. Regula = rule
(18 Nov 1997)
coordinate regulation The expression of many different genes at once.
(09 Oct 1997)
self-regulation A three-stage strategy patients are taught to use in order to end risky health-associated behaviours such as smoking and overeating. 1. Self-monitoring (self-observation), the first stage in self-regulation involves the individual's deliberately attending to and recording his or her own behaviour; 2. Self-evaluation, the second stage, in which the individual assesses what was learned by self-monitoring, such as how often and where one smokes, and uses those observational data to establish health goals or criteria; 3. Self-reinforcement, the third stage, in which the individual rewards him/herself for each behavioural success on the road to that goal, thereby enhancing the chance of reaching it.
(05 Mar 2000)
negative regulation Negative feedback in biological systems mediated by allosteric regulatory enzymes.
(18 Nov 1997)
down-regulation <physiology> Development of a refractory or tolerant state consequent upon repeated administration of a pharmacologically or physiologically active substance.
It is the process that decreases ligand and receptor interactions or reduces the responsiveness of a cell to a stimulus following first exposure.
This is often accompanied by an initial decrease in affinity of receptors for the agent and a subsequent reduction in the number of available receptors expressed on the surface which can result from internalisation of the ligand:receptor complex or from decreased expression of the receptor.
Classically the concept referred to hormone receptors but contemporary usage includes other cell surface receptors.
(03 Jul 1999)
target regulation <physiology> General term for an interaction between neurons and their targets by which target derived signals influence the differentiation of the innervating neurons.
(18 Nov 1997)
enzyme regulation <biochemistry> Control of the rate of a reaction catalyzed by an enzyme by some effector (e.g., inhibitors or activators) or by alteration of some condition (e.g., pH or ionic strength).
(05 Mar 2000)
facility regulation and control Formal voluntary or governmental procedures and standards required of hospitals and health or other facilities to improve operating efficiency, and for the protection of the consumer.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • gene insertion
    À¯ÀüÀÚ »ðÀÔ(ºüÁ®ÀÖ´Â À¯ÀüÀÚ¸¦ »ðÀÔÇϱâ)
  • gene manipulation
    À¯ÀüÀÚ Á¶ÀÛ(ÀÎÀ§ÀûÀ¸·Î À¯ÀüÀÚ¸¦ ¿Å±â°Å³ª ¿°»öü µîÀ» º¯È­½Ã۱â)
  • gene mapping
    À¯ÀüÀÚ Áöµµ(¿°»öü»óÀÇ À¯ÀüÀÚ ÀÚ¸®¸¦ °áÁ¤Çϱâ)
  • gene pool
    À¯ÀüÀÚ Ç®;À¯ÀüÀÚ °ø±Þ¿ø(¸àµ¨ Áý´ÜÀ» ±¸¼ºÇÏ´Â ¸ðµç °³Ã¼°¡ °¡Áö°í ÀÖ´Â À¯ÀüÀÚ Àüü)
  • gene therapy
    À¯ÀüÀÚ ¿ä¹ý(°á¼ÕµÈ À¯ÀüÀÚ¸¦ º¸ÃæÇÏ¿© À¯Àüº´À» °íÄ¡´Â ¿ä¹ý)
  • nif gene
    (»ýÈ­)Áú¼Ò °íÁ¤¿¡ °ü¿©ÇÏ´Â À¯ÀüÀÚ
  • recessive gene
    ¿­¼º À¯ÀüÀÚ
  • regulator(regulatory) gene
    Á¶Àý(Á¦¾î)À¯ÀüÀÚ
  • restorer gene
    ȸº¹ À¯ÀüÀÚ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á